2018 ESC/ESH Guidelines for the management of arterial hypertension.

Introduction The European Society of Cardiology (ESC) and European Society of Hypertension (ESH) jointly issued new guidelines for the management of arterial hypertension, which were presented at the European Society of Cardiology Congress in August 2018. The 2018 ESC/ESH guidelines focus on improving the diagnosis and treatment of hypertension and promoting simple and effective treatment strategies including both lifestyle advice and medications, for poorly controlled blood pressure (BP).

[1]  G. Lip,et al.  ESC Council on hypertension position document on the management of hypertensive emergencies. , 2018, European heart journal. Cardiovascular pharmacotherapy.

[2]  Susanna Price,et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.

[3]  D. Webb,et al.  Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies , 2018, The lancet. Diabetes & endocrinology.

[4]  José R. Banegas,et al.  Relationship between Clinic and Ambulatory Blood‐Pressure Measurements and Mortality , 2018, The New England journal of medicine.

[5]  Karim Ladha,et al.  Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial , 2018, The Lancet.

[6]  Alan Murray,et al.  A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. , 2018, Journal of hypertension.

[7]  Gregory B. Lim.  Hypertension: Low sodium and DASH diet to lower blood pressure , 2018, Nature Reviews Cardiology.

[8]  G. Parati,et al.  Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions , 2018, European heart journal.

[9]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[10]  I. Fernández-Ruíz.  Atherosclerosis: Should we redefine the 'normal' LDL-cholesterol range? , 2018, Nature Reviews Cardiology.

[11]  Adrian F Hernandez,et al.  Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. , 2017, The lancet. Diabetes & endocrinology.

[12]  C. Steinwender,et al.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity. , 2018, The Cochrane database of systematic reviews.

[13]  T. Uejima,et al.  Variable prognostic value of blood pressure response to exercise. , 2018, Journal of cardiology.

[14]  L. Smeeth,et al.  Variations in hypertension awareness, treatment, and control among Ghanaian migrants living in Amsterdam, Berlin, London, and nonmigrant Ghanaians living in rural and urban Ghana – the RODAM study , 2018, Journal of hypertension.

[15]  B. Carlberg,et al.  Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis , 2018, JAMA internal medicine.

[16]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[17]  G. Stone,et al.  Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study , 2017, The Lancet.

[18]  Julie A. Johnson,et al.  Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension , 2017, Journal of clinical hypertension.

[19]  J. Lindholt,et al.  Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial , 2017, The Lancet.

[20]  E. Yeh,et al.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. , 2017, Journal of the American College of Cardiology.

[21]  Neil Chapman,et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.

[22]  P. Heuschmann,et al.  Control of cardiovascular risk factors and its determinants in the general population– findings from the STAAB cohort study , 2017, BMC Cardiovascular Disorders.

[23]  G. Parati,et al.  Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials , 2017, Journal of hypertension.

[24]  S. Yusuf,et al.  Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients , 2017, Hypertension.

[25]  D. Webb,et al.  Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double‐Blind Randomized Controlled Trial , 2017, Journal of the American Heart Association.

[26]  S. Aronson,et al.  Perioperative Management of High-Risk Patients: Going Beyond "Avoid Hypoxia and Hypotension". , 2017, JAMA.

[27]  S. Jaber,et al.  Effect of Individualized vs Standard Blood Pressure Management Strategies on Postoperative Organ Dysfunction Among High-Risk Patients Undergoing Major Surgery: A Randomized Clinical Trial , 2017, JAMA.

[28]  E. O’Brien,et al.  Cardiovascular Risk Associated With White-Coat Hypertension: Con Side of the Argument. , 2017, Hypertension.

[29]  R. Holman,et al.  Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis , 2017, JAMA internal medicine.

[30]  Guy M. McKhann,et al.  Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort , 2017, JAMA neurology.

[31]  G. Lip,et al.  Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardí , 2017, European heart journal. Cardiovascular pharmacotherapy.

[32]  G. Mancia,et al.  Cardiovascular Risk Associated With White-Coat Hypertension: Pro Side of the Argument. , 2017, Hypertension.

[33]  G. Mancia,et al.  Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH) , 2017, European heart journal cardiovascular Imaging.

[34]  G. Mancia,et al.  Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the European Society of Hypertension* , 2017, Journal of hypertension.

[35]  Bonnie J Wakefield,et al.  Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis , 2017, PLoS medicine.

[36]  N. Samani,et al.  Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence , 2017, Hypertension.

[37]  G. Mancia,et al.  The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension. , 2017, Journal of Hypertension.

[38]  A. Cremer,et al.  Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. , 2017, Journal of the American College of Cardiology.

[39]  Pavel S. Roshanov,et al.  Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort , 2017, Anesthesiology.

[40]  G. Mancia,et al.  Protective effects of antihypertensive treatment in patients aged 85 years or older , 2017, Journal of hypertension.

[41]  Nicola Persico,et al.  Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.

[42]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[43]  R. West,et al.  β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction , 2017, Journal of the American College of Cardiology.

[44]  S. Yusuf,et al.  Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials , 2017, The Lancet.

[45]  K. Chien,et al.  Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis , 2017, JAMA internal medicine.

[46]  G. Lip,et al.  Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiologí , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[47]  M. Tetti,et al.  Is There a Role for Genomics in the Management of Hypertension? , 2017, International Journal of Molecular Sciences.

[48]  T. Lehtimäki,et al.  Cardiovascular Risk Factors From Childhood and Midlife Cognitive Performance: The Young Finns Study. , 2017, Journal of the American College of Cardiology.

[49]  G. Chatellier,et al.  Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future , 2017, European heart journal.

[50]  G. Parati,et al.  Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials , 2017, Journal of hypertension.

[51]  P. Dong,et al.  A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. , 2017, International journal of cardiology.

[52]  Liping Liu,et al.  Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials , 2017, Clinical and experimental hypertension.

[53]  A. Dominiczak,et al.  Genomics and Precision Medicine for Clinicians and Scientists in Hypertension. , 2017, Hypertension.

[54]  Jenny Welander,et al.  Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas , 2017, Nature Reviews Endocrinology.

[55]  K. Bhaskaran,et al.  Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study , 2017, British Medical Journal.

[56]  P. Ponikowski,et al.  Carotid body resection for sympathetic modulation in systolic heart failure: results from first‐in‐man study , 2017, European journal of heart failure.

[57]  S. Yusuf,et al.  Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. , 2017, Kidney international.

[58]  G. de Simone,et al.  Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network) , 2017, Journal of the American Heart Association.

[59]  K. Dickstein,et al.  Association of beta‐blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched‐cohort analysis from the High‐Risk Myocardial Infarction Database Initiative , 2017, European journal of heart failure.

[60]  Peter W de Leeuw,et al.  An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. , 2017, Journal of the American Society of Hypertension : JASH.

[61]  G. Mancia,et al.  Blood pressure control in hypertension. Pros and cons of available treatment strategies. , 2017, Journal of hypertension.

[62]  Ivy Shiue,et al.  Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015 , 2017, JAMA.

[63]  Hynek Pikhart,et al.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants , 2017, The Lancet.

[64]  Yuli Huang,et al.  White-coat hypertension is a risk factor for cardiovascular diseases and total mortality , 2017, Journal of hypertension.

[65]  He Gao,et al.  Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk , 2017, Nature Genetics.

[66]  Deepak L. Bhatt,et al.  Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry , 2016, European heart journal.

[67]  E. O’Brien,et al.  Cardiovascular Risk Associated With White-Coat Hypertension , 2017 .

[68]  G. Parati,et al.  SPRINT Blood Pressure , 2017 .

[69]  F. Badilini,et al.  Obesity and ECG left ventricular hypertrophy , 2017, Journal of hypertension.

[70]  G. de Simone,et al.  Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients: The Campania Salute Network , 2017, Hypertension.

[71]  R. Wilcox,et al.  β-Blockers, heart disease and COPD: current controversies and uncertainties , 2016, Thorax.

[72]  C. Cannon,et al.  Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication , 2016, Hypertension.

[73]  S. Achenbach,et al.  Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension , 2016, Journal of the American Heart Association.

[74]  Sudha Seshadri,et al.  Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association , 2016, Hypertension.

[75]  R. Horne,et al.  How to Screen for Non-Adherence to Antihypertensive Therapy , 2016, Current Hypertension Reports.

[76]  E. O’Brien,et al.  The Cardiovascular Risk of White-Coat Hypertension. , 2016, Journal of the American College of Cardiology.

[77]  G. Mancia,et al.  The Heterogeneous Nature of White-Coat Hypertension. , 2016, Journal of the American College of Cardiology.

[78]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[79]  C. Pepine,et al.  Long-Term Mortality in Hypertensive Patients With Coronary Artery DiseaseNovelty and Significance , 2016 .

[80]  B. Davis,et al.  Research Needs to Improve Hypertension Treatment and Control in African Americans , 2016, Hypertension.

[81]  Deepak L. Bhatt,et al.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.

[82]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[83]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[84]  J. Singer,et al.  The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study) , 2016, Hypertension.

[85]  Bo Xiong,et al.  Efficacy and Safety of Spironolactone in Patients with Resistant Hypertension: A Meta-analysis of Randomised Controlled Trials. , 2016, Heart, lung & circulation.

[86]  G. Parati,et al.  Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs meta-analyses of randomized trials , 2016, Journal of hypertension.

[87]  K. Tu,et al.  Cardiovascular Risk in Hypertension in Relation to Achieved Blood Pressure Using Automated Office Blood Pressure Measurement , 2016, Hypertension.

[88]  T. Chao,et al.  Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2‐VASc Score of 1 (Men) or 2 (Women)? , 2016, Journal of the American Heart Association.

[89]  G. Mancia,et al.  Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets , 2016, Blood pressure.

[90]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[91]  W. Riley,et al.  Blood Pressure, Sexual Activity, and Dysfunction in Women With Hypertension: Baseline Findings From the Systolic Blood Pressure Intervention Trial (SPRINT). , 2016, The journal of sexual medicine.

[92]  E. O’Brien,et al.  Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions – Position statement of the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability , 2016, Journal of hypertension.

[93]  D. Lane,et al.  Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.

[94]  G. Lip.  Atrial Fibrillation in Patients With Hypertension: Trajectories of Risk Factors in Yet Another Manifestation of Hypertensive Target Organ Damage. , 2016, Hypertension.

[95]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[96]  S. Yusuf,et al.  Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study , 2016, The Lancet.

[97]  V. Beral,et al.  Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents , 2016, The Lancet.

[98]  G. Lip,et al.  Stroke prevention in atrial fibrillation , 2016, The Lancet.

[99]  M. Myers.  A Short History of Automated Office Blood Pressure – 15 Years to SPRINT , 2016, Journal of clinical hypertension.

[100]  G. Parati,et al.  Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events – meta-analyses of randomized trials , 2016, Journal of hypertension.

[101]  M. Woodward,et al.  Strategies to meet the need for long-term data , 2016, Journal of hypertension.

[102]  G. Lip,et al.  From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency , 2016, Journal of Human Hypertension.

[103]  J. Paton,et al.  Unilateral Carotid Body Resection in Resistant Hypertension , 2016, JACC. Basic to translational science.

[104]  J. Staessen,et al.  Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension , 2016, Hypertension.

[105]  J. Redón,et al.  Isolated Systolic Hypertension in Young People Is Not Spurious and Should Be Treated: Con Side of the Argument , 2016, Hypertension.

[106]  S. Yusuf,et al.  Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies , 2016, The Lancet.

[107]  A. Dominiczak,et al.  2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. , 2016, Journal of hypertension.

[108]  Manish Saxena,et al.  Device-based Therapy for Hypertension , 2016, Current Hypertension Reports.

[109]  Lenore J Launer,et al.  Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.

[110]  J. Cockcroft,et al.  Isolated Systolic Hypertension in Young People Is Not Spurious and Should Be Treated: Pro Side of the Argument. , 2016, Hypertension.

[111]  A. Kaltoft,et al.  Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial , 2016, Journal of hypertension.

[112]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[113]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[114]  D. Hanley,et al.  Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. , 2016, The New England journal of medicine.

[115]  J. Staessen,et al.  Impact and pitfalls of scaling of left ventricular and atrial structure in population-based studies , 2016, Journal of hypertension.

[116]  G. Parati,et al.  Hypertension in Chronic Kidney Disease Part 2: Role of Ambulatory and Home Blood Pressure Monitoring for Assessing Alterations in Blood Pressure Variability and Blood Pressure Profiles , 2016, Hypertension.

[117]  Mark Woodward,et al.  Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke , 2016, Stroke.

[118]  N. Markandu,et al.  Modest Salt Reduction Lowers Blood Pressure and Albumin Excretion in Impaired Glucose Tolerance and Type 2 Diabetes Mellitus: A Randomized Double-Blind Trial , 2016, Hypertension.

[119]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.

[120]  A. Dominiczak,et al.  An Expert Opinion From the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. , 2016, Hypertension.

[121]  G. Mancia,et al.  Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials , 2016, Hypertension.

[122]  M. Nieminen,et al.  Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals , 2016, Journal of hypertension.

[123]  Ada C. Stefanescu Schmidt,et al.  Treatment of Hypertension in Coarctation of the Aorta , 2016, Current Treatment Options in Cardiovascular Medicine.

[124]  A. Park,et al.  Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies , 2016, British Medical Journal.

[125]  Mahboob Rahman,et al.  Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[126]  S. Yusuf,et al.  Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[127]  S. Yusuf,et al.  Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[128]  S. Yusuf,et al.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[129]  K. Kario,et al.  Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive PatientsNovelty and Significance , 2016 .

[130]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials , 2016, Journal of hypertension.

[131]  D. Tousoulis,et al.  White-coat hypertension and cardiovascular events: a meta-analysis , 2016, Journal of hypertension.

[132]  Stefan Störk,et al.  EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries , 2016, European journal of preventive cardiology.

[133]  G. Mancia.  Clinical significance of white-coat hypertension. , 2016, Journal of hypertension.

[134]  G. Mancia,et al.  Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. , 2016, European heart journal.

[135]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[136]  G. Mancia,et al.  No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial , 2016, Blood pressure.

[137]  G. Parati,et al.  Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure – meta-analyses of randomized trials , 2016, Journal of hypertension.

[138]  Bo Carlberg,et al.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .

[139]  Otto Mayer,et al.  Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients , 2016, Blood pressure.

[140]  Yilong Wang,et al.  Relationship between Blood Pressure and Outcomes in Acute Ischemic Stroke Patients Administered Lytic Medication in the TIMS-China Study , 2016, PloS one.

[141]  Sandosh Padmanabhan,et al.  Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial , 2016, The lancet. Diabetes & endocrinology.

[142]  M. Woodward,et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.

[143]  G. Liu,et al.  Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults. , 2016, The Cochrane database of systematic reviews.

[144]  G. Parati,et al.  Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis , 2016, PloS one.

[145]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[146]  J. Banegas,et al.  Ambulatory blood pressure monitoring in daily clinical practice – the Spanish ABPM Registry experience , 2016, European journal of clinical investigation.

[147]  Thalia Shoshana Field,et al.  Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial , 2016, Hypertension.

[148]  T. N. Harrison,et al.  Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery , 2013, Journal of hypertension.

[149]  Thomas R Fanshawe,et al.  Combined pharmacotherapy and behavioural interventions for smoking cessation. , 2016, The Cochrane database of systematic reviews.

[150]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[151]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[152]  Volkmar Falk,et al.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.

[153]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[154]  D. Goff,et al.  Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. , 2015, Hypertension.

[155]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[156]  Isla Mackenzie,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[157]  G. Mancia,et al.  Antihypertensive Medications, Loop Diuretics, and Risk of Hip Fracture in the Elderly: A Population-Based Cohort Study of 81,617 Italian Patients Newly Treated Between 2005 and 2009 , 2015, Drugs & Aging.

[158]  A. Khera,et al.  Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study. , 2015, Journal of the American College of Cardiology.

[159]  G. de Simone,et al.  Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. , 2015, International journal of cardiology.

[160]  V. Conn,et al.  Interventions to Improve Medication Adherence in Hypertensive Patients: Systematic Review and Meta-analysis , 2015, Current Hypertension Reports.

[161]  G. Bakris,et al.  The double challenge of resistant hypertension and chronic kidney disease , 2015, The Lancet.

[162]  L. Hinton,et al.  The Effect of Self-Monitoring of Blood Pressure on Medication Adherence and Lifestyle Factors: A Systematic Review and Meta-Analysis. , 2015, American journal of hypertension.

[163]  F. Messerli,et al.  Drug induced hypertension--An unappreciated cause of secondary hypertension. , 2015, European journal of pharmacology.

[164]  K. Tsoi,et al.  Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. , 2015, JAMA internal medicine.

[165]  A. Dominiczak,et al.  Serum uric acid and the risk of cardiovascular and renal disease. , 2015, Journal of hypertension.

[166]  G. Chatellier,et al.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. , 2015, European heart journal.

[167]  M. Olsen,et al.  Effective risk stratification in patients with moderate cardiovascular risk using albuminuria and atherosclerotic plaques in the carotid arteries , 2015, Journal of hypertension.

[168]  A. Binia,et al.  Daily potassium intake and sodium-to-potassium ratio in the reduction of blood pressure: a meta-analysis of randomized controlled trials , 2015, Journal of hypertension.

[169]  V. Aboyans,et al.  The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. , 2015, Atherosclerosis.

[170]  G. Mancia,et al.  Adverse Prognostic Value of Persistent Office Blood Pressure Elevation in White Coat Hypertension , 2015, Hypertension.

[171]  C. Reid,et al.  Rate of change in renal function and mortality in elderly treated hypertensive patients. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[172]  J. Saver,et al.  Effect of Blood Pressure Lowering in Early Ischemic Stroke: Meta-Analysis , 2015, Stroke.

[173]  P. Rothwell,et al.  Short-term blood pressure variability in acute stroke: post hoc analysis of the controlling hypertension and hypotension immediately post stroke and continue or stop post-stroke antihypertensives collaborative study trials. , 2015, Stroke.

[174]  H. Kamel,et al.  Left Atrial Enlargement and Stroke Recurrence: The Northern Manhattan Stroke Study , 2015, Stroke.

[175]  J. Schneider,et al.  Vascular contributions to cognitive impairment and dementia including Alzheimer's disease , 2015, Alzheimer's & Dementia.

[176]  J. Gottdiener,et al.  Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)†. , 2015, European heart journal cardiovascular Imaging.

[177]  Rong Zhao,et al.  Blood Pressure Reduction in the Acute Phase of an Ischemic Stroke Does Not Improve Short- or Long-Term Dependency or Mortality , 2015, Medicine.

[178]  P. Gosse,et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.

[179]  L. Brewster,et al.  Effects of Thiazide-Type and Thiazide-Like Diuretics on Cardiovascular Events and Mortality: Systematic Review and Meta-Analysis , 2015, Hypertension.

[180]  J. Kostis,et al.  Head-to-Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects , 2015, Hypertension.

[181]  A. Stanton,et al.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial , 2015, The Lancet.

[182]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[183]  Thalia Shoshana Field,et al.  Can Blood Pressure Be Lowered Safely in Older Adults with Lacunar Stroke? The Secondary Prevention of Small Subcortical Strokes Study Experience , 2015, Journal of the American Geriatrics Society.

[184]  P. Donnelly,et al.  A comparison of cardiac computerized tomography and exercise stress electrocardiogram test for the investigation of stable chest pain: the clinical results of the CAPP randomized prospective trial. , 2015, European heart journal cardiovascular Imaging.

[185]  G. Aurigemma,et al.  Cardiovascular risk in relation to a new classification of hypertensive left ventricular geometric abnormalities , 2015, Journal of hypertension.

[186]  E. Seely,et al.  Effects of hormone therapy on blood pressure , 2015, Menopause.

[187]  R. Whitbourn,et al.  First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension , 2015, Hypertension.

[188]  Michael E. Hall,et al.  Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. , 2015, Circulation research.

[189]  G. Mancia,et al.  Clinical value of ambulatory blood pressure: evidence and limits. , 2015, Circulation research.

[190]  G. Parati,et al.  Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. , 2015, Circulation research.

[191]  V. Aboyans,et al.  2014 ESC Guidelines on the Diagnosis and Treatment of Aortic Diseases , 2015 .

[192]  T. Chao,et al.  Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? , 2015, Journal of the American College of Cardiology.

[193]  A. Althouse,et al.  Uric Acid Determination in Gestational Hypertension , 2015, Reproductive Sciences.

[194]  E. T. Investigators,et al.  Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial , 2015, The Lancet.

[195]  K. Rahimi,et al.  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.

[196]  A. Turchin,et al.  Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study , 2015, BMJ : British Medical Journal.

[197]  P. Greenland,et al.  Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. , 2015, Journal of the American College of Cardiology.

[198]  M. Woodward,et al.  Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. , 2015, Annals of internal medicine.

[199]  Evelyn P Whitlock,et al.  Diagnostic and Predictive Accuracy of Blood Pressure Screening Methods With Consideration of Rescreening Intervals: A Systematic Review for the U.S. Preventive Services Task Force , 2015, Annals of Internal Medicine.

[200]  M. Paech,et al.  The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014 , 2015, The Australian & New Zealand journal of obstetrics & gynaecology.

[201]  L. Mbuagbaw,et al.  Effect of green tea supplementation on blood pressure among overweight and obese adults: a systematic review and meta-analysis , 2015, Journal of hypertension.

[202]  A. Gimenez-Roqueplo,et al.  Paraganglioma and phaeochromocytoma: from genetics to personalized medicine , 2015, Nature Reviews Endocrinology.

[203]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – Overview and meta-analyses , 2015, Journal of hypertension.

[204]  M. Zennaro,et al.  An update on novel mechanisms of primary aldosteronism. , 2015, The Journal of endocrinology.

[205]  J. Václavík,et al.  Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension: Six-Month Results From the Prague-15 Study , 2015, Hypertension.

[206]  G. Mancia,et al.  White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis , 2015, Journal of hypertension.

[207]  M. Böhm,et al.  Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension , 2015, Hypertension.

[208]  A. Conca,et al.  Sexual Dysfunction Related to Drugs: A Critical Review. Part IV: Cardiovascular Drugs , 2014, Pharmacopsychiatry.

[209]  T. Ogihara,et al.  Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial , 2014, Hypertension Research.

[210]  Elie N. Mouhayar,et al.  Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. , 2015, Critical reviews in oncology/hematology.

[211]  J. Banegas,et al.  High prevalence of masked uncontrolled hypertension in people with treated hypertension. , 2014, European heart journal.

[212]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials , 2014, Journal of hypertension.

[213]  G. Parati,et al.  Effect of Long-Term Antihypertensive Treatment on White-Coat Hypertension , 2014, Hypertension.

[214]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials , 2014, Journal of hypertension.

[215]  K. Kario,et al.  Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13 844 patients with hypertension , 2014, Journal of hypertension.

[216]  G. Mancia,et al.  Prognostic Significance of Left Atrial Enlargement in a General Population: Results of the PAMELA Study , 2014, Hypertension.

[217]  S. Laurent,et al.  Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. , 2014, European heart journal.

[218]  P. Willeit,et al.  Left Ventricular Mass and the Risk of Sudden Cardiac Death: A Population‐Based Study , 2014, Journal of the American Heart Association.

[219]  A. Alexandrov,et al.  Intensive blood pressure reduction in acute intracerebral hemorrhage , 2014, Neurology.

[220]  B. Williams,et al.  Updated National and International Hypertension Guidelines: A Review of Current Recommendations , 2014, Drugs.

[221]  M. Woodward,et al.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. , 2014, The New England journal of medicine.

[222]  S. Laurent,et al.  Dose-Dependent Arterial Destiffening and Inward Remodeling After Olmesartan in Hypertensives With Metabolic Syndrome , 2014, HYPERTENSION.

[223]  Susanna Price,et al.  2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). , 2014, European heart journal.

[224]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[225]  S. Pocock,et al.  to improve adherence : results from FOCUS ( Fixed-dose Combination Drug for Secondary Cardiovascular Prevention ) Project , 2014 .

[226]  M. Burnier.  Managing ‘resistance’: is adherence a target for treatment? , 2014, Current opinion in nephrology and hypertension.

[227]  P. Okin,et al.  Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review. , 2014, Journal of electrocardiology.

[228]  Emma P Bray,et al.  Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. , 2014, JAMA.

[229]  M. Woodward,et al.  Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data , 2014, The Lancet.

[230]  S. Yusuf,et al.  Urinary sodium and potassium excretion, mortality, and cardiovascular events. , 2014, The New England journal of medicine.

[231]  K. Kalantar-Zadeh,et al.  Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. , 2014, Journal of the American College of Cardiology.

[232]  P. Ridker,et al.  Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. , 2014, Journal of the American College of Cardiology.

[233]  Karien Stronks,et al.  Socioeconomic Inequalities in Stroke Incidence Among Migrant Groups: Analysis of Nationwide Data , 2014, Stroke.

[234]  D. Strauss,et al.  The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy , 2014, Current cardiology reviews.

[235]  D. Thijssen,et al.  The Effect of Black Tea on Blood Pressure: A Systematic Review with Meta-Analysis of Randomized Controlled Trials , 2014, PloS one.

[236]  Hynek Pikhart,et al.  Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data , 2014, BMJ : British Medical Journal.

[237]  Geoffrey A Head,et al.  European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. , 2014, Journal of hypertension.

[238]  C. Bulpitt,et al.  Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial , 2014, Journal of hypertension.

[239]  Tom Greene,et al.  Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[240]  B. Carlberg.  What do we know about the risks of stopping antihypertensive treatment? , 2014, Journal of hypertension.

[241]  J. Paton,et al.  Arteriovenous Anastomosis: Is This the Way to Control Hypertension? , 2014, Hypertension.

[242]  R. Lamuela-Raventós,et al.  Mediterranean Diet Reduces 24-Hour Ambulatory Blood Pressure, Blood Glucose, and Lipids: One-Year Randomized, Clinical Trial , 2014, Hypertension.

[243]  Michael E. Miller,et al.  Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. , 2014, JAMA.

[244]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[245]  A. Zanchetti,et al.  Cohort profile: The Gubbio Population Study. , 2014, International journal of epidemiology.

[246]  Emanuela Falaschetti,et al.  Hypertension management in England: a serial cross-sectional study from 1994 to 2011 , 2014, The Lancet.

[247]  Harry Hemingway,et al.  Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people , 2014, The Lancet.

[248]  L. Ferrari,et al.  Arterial hypertension and cancer , 2014, International journal of cancer.

[249]  F. Messerli,et al.  Secondary arterial hypertension: when, who, and how to screen? , 2014, European heart journal.

[250]  Christopher P Price,et al.  Diagnostic Accuracy of Point-of-Care Tests for Detecting Albuminuria , 2014, Annals of Internal Medicine.

[251]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[252]  Nilesh J Samani,et al.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis , 2014, Heart.

[253]  G. Bruno,et al.  Hospital Admissions for Hypertensive Crisis in the Emergency Departments: A Large Multicenter Italian Study , 2014, PloS one.

[254]  E. Dolan,et al.  Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. , 2014, Journal of vascular surgery.

[255]  J. Cutler,et al.  Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.

[256]  J. Boer,et al.  Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands , 2014, European journal of preventive cardiology.

[257]  L. Køber,et al.  Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study. , 2014, JAMA internal medicine.

[258]  M. Esler.  Sympathetic Nervous System Moves Toward Center Stage in Cardiovascular Medicine: From Thomas Willis to Resistant Hypertension , 2014, Hypertension.

[259]  Yoav Ben-Shlomo,et al.  Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. , 2014, Journal of the American College of Cardiology.

[260]  Michael Böhm,et al.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study , 2014, The Lancet.

[261]  F. Hu,et al.  Long-Term Coffee Consumption and Risk of Cardiovascular Disease: A Systematic Review and a Dose–Response Meta-Analysis of Prospective Cohort Studies , 2014, Circulation.

[262]  I. Valkengoed,et al.  Mortality and Cardiovascular Risk in Patients With a History of Malignant Hypertension: A Case‐Control Study , 2014, Journal of clinical hypertension.

[263]  T. Marwick,et al.  Association of outcome with left ventricular parameters measured by two-dimensional and three-dimensional echocardiography in patients at high cardiovascular risk. , 2014, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[264]  V. Aboyans,et al.  [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2014, Kardiologia polska.

[265]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[266]  A. Shennan,et al.  Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. , 2015, Obstetrics and gynecology.

[267]  Andrew Steptoe,et al.  COHORT PROFILE Cohort Profile : The English Longitudinal Study of Ageing , 2014 .

[268]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[269]  James M. Roberts,et al.  Hypertension in Pregnancy: Executive Summary , 2013 .

[270]  G. Mancia,et al.  The unappreciated importance of blood pressure in recent and older atrial fibrillation trials , 2013, Journal of hypertension.

[271]  L. Tarnow,et al.  Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial , 2013, Journal of hypertension.

[272]  E. O’Brien,et al.  Response to Masked hypertension in untreated and treated patients with diabetes mellitus: attractive but questionable interpretations and response to Is masked hypertension related to diabetes mellitus? , 2013, Hypertension.

[273]  Henk A Marquering,et al.  Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. , 2013, European heart journal.

[274]  C. Otto,et al.  Time to treat hypertension in patients with aortic stenosis. , 2013, Circulation.

[275]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[276]  J. Paton,et al.  The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension , 2013, Nature Communications.

[277]  C. Molina,et al.  Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage , 2013, European journal of neurology.

[278]  Geoffrey A Head,et al.  European Society of Hypertension position paper on ambulatory blood pressure monitoring. , 2013, Journal of hypertension.

[279]  H. Tighiouart,et al.  Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis , 2013, Canadian Medical Association Journal.

[280]  J. Urquhart,et al.  Measuring, analyzing, and managing drug adherence in resistant hypertension. , 2013, Hypertension.

[281]  J. Mayet,et al.  Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery , 2013, Heart.

[282]  K. Kario,et al.  Systolic Blood Pressure After Intravenous Antihypertensive Treatment and Clinical Outcomes in Hyperacute Intracerebral Hemorrhage: The Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study , 2013, Stroke.

[283]  J. Guirguis-Blake.  Pharmacotherapy for mild hypertension. , 2013, American family physician.

[284]  G. Mancia,et al.  Long-Term Prognostic Value of White Coat Hypertension: An Insight From Diagnostic Use of Both Ambulatory and Home Blood Pressure Measurements , 2013, Hypertension.

[285]  C. Stefanadis,et al.  Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies , 2013, Heart.

[286]  M. Woodward,et al.  Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. , 2013, The New England journal of medicine.

[287]  A. Bachoud-Lévi,et al.  Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis , 2013, Journal of hypertension.

[288]  B. Howard,et al.  Lack of Reduction of Left Ventricular Mass in Treated Hypertension: The Strong Heart Study , 2013, Journal of the American Heart Association.

[289]  R. Perera,et al.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[290]  W. Henderson,et al.  Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. , 2013, JAMA.

[291]  P. Elliott,et al.  Effect of lower sodium intake on health: systematic review and meta-analyses , 2013, BMJ : British Medical Journal.

[292]  Dolores Corella,et al.  Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013, The New England journal of medicine.

[293]  M. O'Rourke,et al.  Guidelines on guidelines: focus on isolated systolic hypertension in youth. , 2013, Journal of hypertension.

[294]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.

[295]  Gianfranco Parati,et al.  Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies , 2013, Journal of hypertension.

[296]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[297]  杜昕,et al.  Resistant hypertension , 2013 .

[298]  V. Cornelissen,et al.  Exercise Training for Blood Pressure: A Systematic Review and Meta‐analysis , 2013, Journal of the American Heart Association.

[299]  R. Shamloul,et al.  Erectile dysfunction , 2013, The Lancet.

[300]  K. Flegal,et al.  Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories , 2012 .

[301]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[302]  Helmut Baumgartner,et al.  The 2013 ESH/ESC guidelines for the management of arterial hypertension , 2013 .

[303]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[304]  K. Manhem,et al.  Exercise blood pressure and the risk of future hypertension , 2012, Journal of Human Hypertension.

[305]  S. Yusuf,et al.  Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) , 2012, Hypertension.

[306]  J. Spertus,et al.  Resistant hypertension , 2012, BMJ : British Medical Journal.

[307]  T. Jørgensen,et al.  Impact of Age on the Importance of Systolic and Diastolic Blood Pressures for Stroke Risk: The MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project , 2012, Hypertension.

[308]  D. Wald,et al.  Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. , 2012, The American journal of medicine.

[309]  Markus Schlaich,et al.  New drugs, procedures, and devices for hypertension , 2012, The Lancet.

[310]  S. Kjeldsen,et al.  Relation Between Change in Blood Pressure in Acute Stroke and Risk of Early Adverse Events and Poor Outcome , 2012, Stroke.

[311]  Giuseppe Mancia,et al.  Short- and long-term blood pressure variability: present and future. , 2012, Hypertension.

[312]  G. Stergiou,et al.  Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis , 2012, Journal of hypertension.

[313]  S. Daskalopoulou,et al.  The impact of physical activity on mortality in patients with high blood pressure: a systematic review , 2012, Journal of hypertension.

[314]  Lu Gao,et al.  Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data , 2012, The Lancet.

[315]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[316]  G. Mancia,et al.  Blood pressure control in Italy: analysis of clinical data from 2005–2011 surveys on hypertension , 2012, Journal of hypertension.

[317]  G. Mancia,et al.  Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers , 2012, Journal of hypertension.

[318]  Jens Jordan,et al.  Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. , 2012, Journal of hypertension.

[319]  S. Shaftman,et al.  Initial Monotherapy and Combination Therapy and Hypertension Control the First Year , 2012, Hypertension.

[320]  S. Yusuf,et al.  Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studie , 2012, Journal of hypertension.

[321]  J. McMurray,et al.  Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. , 2012, Journal of the American College of Cardiology.

[322]  D. Flum,et al.  β-blocker continuation after noncardiac surgery: a report from the surgical care and outcomes assessment program. , 2012, Archives of surgery.

[323]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[324]  J. Banegas,et al.  Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study , 2012, Journal of hypertension.

[325]  N. Brown,et al.  Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome , 2012, Hypertension.

[326]  J. Mant,et al.  Do differences in blood pressure between arms matter? , 2012, The Lancet.

[327]  Obioha C Ukoumunne,et al.  Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis , 2012, The Lancet.

[328]  I. Chetter,et al.  Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. , 2012, Atherosclerosis.

[329]  G. Mancia,et al.  Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. , 2012, The American journal of cardiology.

[330]  G. Parati,et al.  What are the real determinants of the ambulatory arterial stiffness index? , 2012, Journal of hypertension.

[331]  Carl Heneghan,et al.  Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies , 2012, Journal of hypertension.

[332]  C. Bulpitt,et al.  Blood pressure control in the Hypertension in the Very Elderly Trial (HYVET) , 2012, Journal of Human Hypertension.

[333]  J. Filipovský,et al.  Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. , 2012, Journal of hypertension.

[334]  E. O’Brien,et al.  Significance of White-Coat Hypertension in Older Persons With Isolated Systolic Hypertension: A Meta-Analysis Using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Population , 2012, Hypertension.

[335]  K. Liestøl,et al.  Upper Normal Blood Pressures Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men: A 35-Year Follow-Up Study , 2012, Hypertension.

[336]  G. Breithardt,et al.  Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial Running title: Goette et al.; The ANTIPAF Trial , 2010 .

[337]  Avis J. Thomas,et al.  Lifetime risks of cardiovascular disease. , 2012, The New England journal of medicine.

[338]  Yi Wang,et al.  Improved Left Ventricular Mass Quantification With Partial Voxel Interpolation: In Vivo and Necropsy Validation of a Novel Cardiac MRI Segmentation Algorithm , 2012, Circulation. Cardiovascular imaging.

[339]  S. Bergmann,et al.  Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. , 2011, Atherosclerosis.

[340]  S. Yusuf,et al.  Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). , 2012, Journal of the American College of Cardiology.

[341]  M. Volpe,et al.  Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan / Amlodipine / Hydrochlorothiazide Combination , 2012 .

[342]  K. Narkiewicz,et al.  TREATMENT OF HYPERTENSION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) , 2012 .

[343]  G. Jürgens,et al.  Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). , 2012, American journal of hypertension.

[344]  R. Fagard.  Resistant hypertension , 2011, Heart.

[345]  F. Irie,et al.  Mild Retinopathy Is a Risk Factor for Cardiovascular Mortality in Japanese With and Without Hypertension: The Ibaraki Prefectural Health Study , 2011, Circulation.

[346]  M. Burnier,et al.  Nutrition in cardiovascular disease: salt in hypertension and heart failure. , 2011, European heart journal.

[347]  Mike Kirby,et al.  Guidelines on the management of cardiovascular diseases during pregnancy The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology ( ESC ) , 2011 .

[348]  P. Kirchhof,et al.  Bleeding risk assessment and management in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[349]  P. Muntner,et al.  Predictors of Decline in Medication Adherence: Results From the Cohort Study of Medication Adherence Among Older Adults , 2011, Hypertension.

[350]  Adrian P Mander,et al.  Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial , 2011, The Lancet.

[351]  S. Yusuf,et al.  Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) , 2011, Circulation.

[352]  J. Guindo,et al.  Clustering of target organ damage increases mortality after acute coronary syndromes in patients with arterial hypertension , 2011, Journal of Human Hypertension.

[353]  L. Qin,et al.  Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. , 2011, Journal of the American College of Cardiology.

[354]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[355]  T. Ogihara,et al.  Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial , 2011, Journal of hypertension.

[356]  S. Ebrahim,et al.  Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). , 2011, American journal of hypertension.

[357]  G. MacGregor,et al.  Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials , 2011, The Lancet.

[358]  Michael J Pencina,et al.  Carotid-wall intima-media thickness and cardiovascular events. , 2011, The New England journal of medicine.

[359]  S. Yusuf,et al.  Changes in albuminuria predict mortality and morbidity in patients with vascular disease. , 2011, Journal of the American Society of Nephrology : JASN.

[360]  S. Kanba,et al.  Midlife and Late-Life Blood Pressure and Dementia in Japanese Elderly: The Hisayama Study , 2011, Hypertension.

[361]  P. Gill,et al.  Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study , 2011, BMC family practice.

[362]  N. Roberts,et al.  Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review , 2011, BMJ : British Medical Journal.

[363]  S. Bangalore,et al.  Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[364]  S. Nesbitt,et al.  A Titrate‐to‐Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed‐Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide , 2011, Journal of clinical hypertension.

[365]  T. Berl,et al.  Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. , 2011, European heart journal.

[366]  G. V. van Montfrans,et al.  Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis , 2011, Journal of hypertension.

[367]  E. Lewis,et al.  Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[368]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[369]  Amy Earley,et al.  Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier , 2011, Annals of Internal Medicine.

[370]  M. Woodward,et al.  Meta-Analysis: Impact of Drug Class on Adherence to Antihypertensives , 2011, Circulation.

[371]  Eliseo Guallar,et al.  Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study , 2011, European heart journal.

[372]  Rowena J Dolor,et al.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. , 2011, Journal of the American College of Cardiology.

[373]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[374]  K. Reynolds,et al.  Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension: A Meta-Analysis , 2012 .

[375]  G. Mancia,et al.  Better compliance to antihypertensive medications reduces cardiovascular risk , 2011, Journal of hypertension.

[376]  M. Caulfield,et al.  Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial−Blood Pressure Lowering Arm (ASCOT-BPLA) , 2011, Journal of hypertension.

[377]  D. Jatužis,et al.  The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial , 2011, The Lancet.

[378]  B. Williams.  High blood pressure in young people and premature death , 2011, BMJ : British Medical Journal.

[379]  F. Rasmussen,et al.  Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts , 2011, BMJ : British Medical Journal.

[380]  M. Burnier,et al.  Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril , 2011, International journal of clinical practice.

[381]  P. Anyfanti,et al.  Hypertension and sexual dysfunction: time to act. , 2011, Journal of hypertension.

[382]  Carole Dufouil,et al.  Antihypertensive Treatment and Change in Blood Pressure Are Associated With the Progression of White Matter Lesion Volumes: The Three-City (3C)–Dijon Magnetic Resonance Imaging Study , 2011, Circulation.

[383]  J Urquhart,et al.  Effects on blood pressure and cardiovascular risk of variations in patients’ adherence to prescribed antihypertensive drugs: role of duration of drug action , 2011, International journal of clinical practice.

[384]  A. Viera,et al.  Do Clinicians Tell Patients They Have Prehypertension? , 2011, The Journal of the American Board of Family Medicine.

[385]  S. Laurent,et al.  Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients , 2010, Journal of hypertension.

[386]  Enrico Vassallo,et al.  Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. , 2010, Journal of the American College of Cardiology.

[387]  Yikyung Park,et al.  Body-mass index and mortality among 1.46 million white adults. , 2010, The New England journal of medicine.

[388]  G. Parati,et al.  Role of home blood pressure telemonitoring in hypertension management: an update , 2010, Blood pressure monitoring.

[389]  C. Cannon,et al.  What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial , 2010, Circulation.

[390]  P. Sager,et al.  Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial , 2010, Hypertension.

[391]  Rosanna Abbate,et al.  Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. , 2010, The American journal of clinical nutrition.

[392]  G. Mensah,et al.  Treatment and control of high blood pressure in adults. , 2010, Cardiology clinics.

[393]  C. Dufouil,et al.  Long-term reduction in aortic stiffness: a 5.3-year follow-up in routine clinical practice , 2010, Journal of hypertension.

[394]  A. Dogan,et al.  Acute effects of passive smoking on blood pressure and heart rate in healthy females , 2010 .

[395]  L. Ruilope,et al.  Long-term renal survival in malignant hypertension. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[396]  F. Greenway,et al.  Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile , 2010, Hypertension Research.

[397]  R. Erbel,et al.  Echocardiography in aortic diseases: EAE recommendations for clinical practice. , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[398]  Rod S Taylor,et al.  Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.

[399]  C. Agyemang,et al.  Masked Hypertension: Evidence of the Need to Treat , 2010, Current hypertension reports.

[400]  Christodoulos Stefanadis,et al.  Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. , 2010, European heart journal.

[401]  C. Bulpitt,et al.  Effects of antihypertensive treatment after acute stroke in the Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial , 2010, The Lancet Neurology.

[402]  Richard J McManus,et al.  Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial , 2010, The Lancet.

[403]  G. Mancia,et al.  Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice , 2010, Journal of hypertension.

[404]  G. de Simone,et al.  Does Information on Systolic and Diastolic Function Improve Prediction of a Cardiovascular Event by Left Ventricular Hypertrophy in Arterial Hypertension? , 2010, Hypertension.

[405]  R. Fagard,et al.  Orthostatic Hypotension Is a More Robust Predictor of Cardiovascular Events Than Nighttime Reverse Dipping in Elderly , 2010, Hypertension.

[406]  Jonathan Mant,et al.  Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials , 2010, Annals of medicine.

[407]  Yasmin,et al.  Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ , 2010, European heart journal.

[408]  F. Rutten,et al.  Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. , 2010, Archives of internal medicine.

[409]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[410]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[411]  Eric Boerwinkle,et al.  Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. , 2010, Journal of the American College of Cardiology.

[412]  G. Bakris,et al.  Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial , 2010, The Lancet.

[413]  T. Hansen,et al.  Risk prediction is improved by adding markers of subclinical organ damage to SCORE. , 2010, European heart journal.

[414]  Kirsten Bibbins-Domingo,et al.  Projected effect of dietary salt reductions on future cardiovascular disease. , 2010, The New England journal of medicine.

[415]  E. O’Brien,et al.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension , 2010, The Lancet.

[416]  N. Poulter,et al.  Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis , 2010, Hypertension.

[417]  Martin G Myers,et al.  Measurement of blood pressure in the office: recognizing the problem and proposing the solution. , 2010, Hypertension.

[418]  D. Conen,et al.  Risk for Incident Atrial Fibrillation in Patients Who Receive Antihypertensive Drugs , 2010, Annals of Internal Medicine.

[419]  Teemu J Niiranen,et al.  Home-Measured Blood Pressure Is a Stronger Predictor of Cardiovascular Risk Than Office Blood Pressure: The Finn-Home Study , 2009, Hypertension.

[420]  B. Astor,et al.  Change in estimated GFR associates with coronary heart disease and mortality. , 2009, Journal of the American Society of Nephrology : JASN.

[421]  G. Lip,et al.  Improving survival of malignant hypertension patients over 40 years. , 2009, American journal of hypertension.

[422]  A. Dominiczak,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. , 2009, Journal of hypertension.

[423]  L. Thijs,et al.  Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies , 2009, Hypertension.

[424]  B. Williams.  Resistant hypertension: an unmet treatment need , 2009, The Lancet.

[425]  Alessandro Filippi,et al.  Adherence to Antihypertensive Medications and Cardiovascular Morbidity Among Newly Diagnosed Hypertensive Patients , 2009, Circulation.

[426]  I. Graham,et al.  Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. , 2009, Journal of the American College of Cardiology.

[427]  G. Parati,et al.  Baseline Values but Not Treatment-Induced Changes in Carotid Intima-Media Thickness Predict Incident Cardiovascular Events in Treated Hypertensive Patients: Findings in the European Lacidipine Study on Atherosclerosis (ELSA) , 2009, Circulation.

[428]  A. Franx,et al.  Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial , 2009, The Lancet.

[429]  S. Oparil,et al.  Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension: Results From a Randomized Trial , 2009, Hypertension.

[430]  J. Staessen,et al.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial , 2009, The Lancet.

[431]  G. Mancia,et al.  Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension , 2009, Journal of hypertension.

[432]  Mark Woodward,et al.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[433]  G. Mancia,et al.  Long-Term Risk of Sustained Hypertension in White-Coat or Masked Hypertension , 2009, Hypertension.

[434]  A. Da Silva,et al.  Beta blockers for peripheral arterial disease. , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[435]  S. Yusuf,et al.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study , 2009, Journal of hypertension.

[436]  M. Kaste,et al.  Relationship of Blood Pressure, Antihypertensive Therapy, and Outcome in Ischemic Stroke Treated With Intravenous Thrombolysis: Retrospective Analysis From Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) , 2009, Stroke.

[437]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[438]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[439]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[440]  G. Mancia,et al.  When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal , 2009, Journal of hypertension.

[441]  C. Albert,et al.  Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. , 2009, Circulation.

[442]  J. Engvall,et al.  Masked nocturnal hypertension—a novel marker of risk in type 2 diabetes , 2009, Diabetologia.

[443]  A. Maggioni,et al.  Valsartan for prevention of recurrent atrial fibrillation. , 2009, The New England journal of medicine.

[444]  M. Nieminen,et al.  Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment: The Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) , 2009, Circulation.

[445]  Sonia S Anand,et al.  A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. , 2009, Archives of internal medicine.

[446]  M. Woodward,et al.  Lowering blood pressure reduces renal events in type 2 diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[447]  T. LeCompte,et al.  Vascular Structure and Function Is Correlated to Cognitive Performance and White Matter Hyperintensities in Older Hypertensive Patients With Subjective Memory Complaints , 2009, Stroke.

[448]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, Lancet.

[449]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.

[450]  D. Wald,et al.  Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials , 2010 .

[451]  D. Levy,et al.  Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[452]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[453]  K. Asayama,et al.  Day-by-Day Variability of Blood Pressure and Heart Rate at Home as a Novel Predictor of Prognosis: The Ohasama Study , 2008, Hypertension.

[454]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[455]  M. Criqui,et al.  Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. , 2008, Journal of the American College of Cardiology.

[456]  P. Gosse,et al.  Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage , 2008, Journal of hypertension.

[457]  Ivan S. Salgo,et al.  Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[458]  Pierre-François Plouin,et al.  Masked hypertension: a systematic review. , 2008, Journal of hypertension.

[459]  K. Ferdinand,et al.  Hypertensive Urgencies in the Emergency Department: Evaluating Blood Pressure Response to Rest and to Antihypertensive Drugs With Different Profiles , 2008, Journal of clinical hypertension.

[460]  V. Froelicher,et al.  The blood pressure response to dynamic exercise testing: a systematic review. , 2008, Progress in cardiovascular diseases.

[461]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[462]  Yutaka Imai,et al.  European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring , 2008, Journal of hypertension.

[463]  A Hofman,et al.  Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. , 2008, JAMA.

[464]  G. Mancia,et al.  Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis , 2008, Journal of hypertension.

[465]  N. Chapman,et al.  Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial , 2008, Circulation.

[466]  P. Sever,et al.  Systolic pressure is all that matters , 2008, The Lancet.

[467]  David F Yankelevitz,et al.  Left ventricular papillary muscles and trabeculae are significant determinants of cardiac MRI volumetric measurements: effects on clinical standards in patients with advanced systolic dysfunction. , 2008, International journal of cardiology.

[468]  D. Singer,et al.  Management of hypertension in peripheral arterial disease: does the choice of drugs matter? , 2008, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[469]  John Urquhart,et al.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2008, BMJ : British Medical Journal.

[470]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[471]  V. Musini,et al.  Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review , 2008, Journal of Human Hypertension.

[472]  A. Shennan,et al.  Assessment of proteinuria in pregnancy , 2008, BMJ : British Medical Journal.

[473]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[474]  G. Mancia,et al.  Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy , 2008, Journal of hypertension.

[475]  Aeilko H. Zwinderman,et al.  Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis , 2008, Canadian Medical Association Journal.

[476]  A. Zanchetti,et al.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial , 2008, Journal of hypertension.

[477]  J. Banegas,et al.  Clinical characteristics of isolated clinic hypertension , 2008, Journal of hypertension.

[478]  C M Otto,et al.  The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape , 2008, Heart.

[479]  G. Mancia,et al.  Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure , 2008, Blood pressure monitoring.

[480]  B. Davis,et al.  Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2008, Archives of internal medicine.

[481]  Jan A. Staessen,et al.  Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension , 2008, Hypertension.

[482]  M. D. De Buyzere,et al.  Management of hypertension in peripheral arterial disease. , 2008, Progress in cardiovascular diseases.

[483]  Yikyung Park,et al.  Physical activity recommendations and decreased risk of mortality. , 2007, Archives of internal medicine.

[484]  G. Mancia,et al.  Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima–media thickness , 2007, Journal of hypertension.

[485]  R. Fagard,et al.  Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis , 2007, Journal of hypertension.

[486]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[487]  G. Mancia,et al.  Neurogenic Abnormalities in Masked Hypertension , 2007, Hypertension.

[488]  A. Tveit,et al.  Candesartan in the prevention of relapsing atrial fibrillation. , 2007, International journal of cardiology.

[489]  G. Mancia,et al.  Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study , 2007, Hypertension.

[490]  R. Townsend,et al.  Chemotherapy agents and hypertension: A focus on angiogenesis blockade , 2007, Current hypertension reports.

[491]  P. Koudstaal,et al.  Silent brain infarcts: a systematic review , 2007, The Lancet Neurology.

[492]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[493]  N. Cook,et al.  Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP) , 2007, BMJ : British Medical Journal.

[494]  J. Elefteriades,et al.  Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. , 2007, The Annals of thoracic surgery.

[495]  K. Greenlund,et al.  Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. , 2007, American journal of hypertension.

[496]  M. Mattarello,et al.  Detecting and Treating Primary Aldosteronism , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[497]  J. Le Heuzey,et al.  Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. , 2007, European heart journal.

[498]  R. Devereux,et al.  Left Atrial Size and Risk of Major Cardiovascular Events During Antihypertensive Treatment: Losartan Intervention for Endpoint Reduction in Hypertension Trial , 2007, Hypertension.

[499]  R. Stafford,et al.  Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. , 2007, Archives of internal medicine.

[500]  杨勇,et al.  Erectile dysfunction , 2006 .

[501]  G. V. van Montfrans,et al.  Ethnic disparities in the incidence, presentation and complications of malignant hypertension , 2006, Journal of hypertension.

[502]  H. Struijker‐Boudier,et al.  Expert consensus document on arterial stiffness: methodological issues and clinical applications. , 2006, European heart journal.

[503]  G. Bakris,et al.  Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review , 2006, Hypertension.

[504]  M. Pfeffer,et al.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, American heart journal.

[505]  J. Staessen,et al.  Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials , 2006, Stroke.

[506]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[507]  E. Salpeter,et al.  Meta-Analysis: Effect of Long-Acting -Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths , 2006, Annals of Internal Medicine.

[508]  M. Woodward,et al.  Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial , 2006, Journal of hypertension.

[509]  Roberto Sega,et al.  Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure , 2006, Hypertension.

[510]  S. Oparil,et al.  Feasibility of treating prehypertension with an angiotensin-receptor blocker. , 2006, The New England journal of medicine.

[511]  Jeroen J. Bax,et al.  The long-term prognostic value of the resting and postexercise ankle-brachial index. , 2006, Archives of internal medicine.

[512]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[513]  Bryan Williams,et al.  Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials , 2006, Journal of hypertension.

[514]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[515]  G. Mancia,et al.  New-onset diabetes and antihypertensive drugs. , 2006, Journal of Hypertension.

[516]  G. Mancia,et al.  Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds , 2005, Journal of hypertension.

[517]  Li-sheng Liu,et al.  The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients , 2005, Journal of hypertension.

[518]  M. Schull,et al.  Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study , 2005, The Lancet.

[519]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[520]  G. Dibona.  Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[521]  F. Fuchs,et al.  Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension , 2005, Journal of Human Hypertension.

[522]  G. Mancia,et al.  Relationship of Office, Home, and Ambulatory Blood Pressure to Blood Glucose and Lipid Variables in the PAMELA Population , 2005, Hypertension.

[523]  D. Rao,et al.  Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. , 2005, European heart journal.

[524]  Roberto Sega,et al.  Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study , 2005, Circulation.

[525]  Barry R. Davis,et al.  Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril , 2005 .

[526]  Empar Lurbe,et al.  Prevalence, Persistence, and Clinical Significance of Masked Hypertension in Youth , 2005, Hypertension.

[527]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[528]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[529]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[530]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[531]  G. Mancia,et al.  Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS—A Randomized Double-Blind Trial , 2004, Stroke.

[532]  G. Mancia,et al.  Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. , 2004, American journal of hypertension.

[533]  E. Vicaut,et al.  Mannheim Intima-Media Thickness Consensus , 2004, Cerebrovascular Diseases.

[534]  M. Nieminen,et al.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. , 2004, JAMA.

[535]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[536]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[537]  Volkan Ozduran,et al.  Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. , 2004, JAMA.

[538]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[539]  B. Brenner,et al.  Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy , 2004, Circulation.

[540]  Richard Doll,et al.  Mortality in relation to smoking: 22 years' observations on female British doctors. , 1980, British medical journal.

[541]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[542]  A. de la Sierra,et al.  Silent cerebral white matter lesions and cognitive function in middle-aged essential hypertensive patients. , 2004, American journal of hypertension.

[543]  D. Rizzoni,et al.  Left Ventricular Concentric Geometry During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients , 2004, Hypertension.

[544]  Gilles Chatellier,et al.  Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. , 2004, JAMA.

[545]  S. Kjeldsen.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[546]  M. Godwin,et al.  Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners , 2004, BMJ : British Medical Journal.

[547]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[548]  G. MacGregor,et al.  Effect of longer-term modest salt reduction on blood pressure. , 2000, The Cochrane database of systematic reviews.

[549]  L. Stead,et al.  Physician advice for smoking cessation. , 2004, The Cochrane database of systematic reviews.

[550]  G. Lip,et al.  Antiplatelet agents and anticoagulants for hypertension. , 2004, The Cochrane database of systematic reviews.

[551]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[552]  G. MacGregor,et al.  How Far Should Salt Intake Be Reduced? , 2003, Hypertension.

[553]  Diederick E. Grobbee,et al.  Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials , 2003, Hypertension.

[554]  L. Magee,et al.  Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis , 2003, BMJ : British Medical Journal.

[555]  L. Appel,et al.  The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives. , 2003, Preventive medicine.

[556]  P. Douglas.  The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. , 2003, Journal of the American College of Cardiology.

[557]  Christopher H Schmid,et al.  Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.

[558]  A. Ducharme,et al.  Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials , 2003, Circulation.

[559]  Peter W de Leeuw,et al.  Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. , 2003, The New England journal of medicine.

[560]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[561]  Peter Sleight,et al.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.

[562]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[563]  Kazuomi Kario,et al.  Morning Surge in Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in Elderly Hypertensives: A Prospective Study , 2003, Circulation.

[564]  R. Norton,et al.  Blood pressure and cardiovascular disease in the Asia Pacific region , 2003 .

[565]  D. Henderson-smart,et al.  Drugs for treatment of very high blood pressure during pregnancy. , 2013, The Cochrane database of systematic reviews.

[566]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[567]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[568]  J. Redón,et al.  Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. , 2002, The New England journal of medicine.

[569]  G. Mancia,et al.  Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey , 2002, Journal of hypertension.

[570]  M. Pfeffer,et al.  Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). , 2002, JAMA.

[571]  Daniel F McCaffrey,et al.  Occurrence of Secondary Ischemic Events Among Persons With Atherosclerotic Vascular Disease , 2002, Stroke.

[572]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[573]  M. Cazzola,et al.  The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. , 2002, Chest.

[574]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2014, The Cochrane database of systematic reviews.

[575]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[576]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[577]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[578]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[579]  P. Ducimetiere,et al.  Aortic Stiffness Is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients , 2001, Hypertension.

[580]  J. Blacher,et al.  Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure , 2001, Circulation.

[581]  Emanuela Falaschetti,et al.  Association Between Smoking and Blood Pressure: Evidence From the Health Survey for England , 2001, Hypertension.

[582]  F. Luft.  Twins in Cardiovascular Genetic Research , 2001, Hypertension.

[583]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[584]  N. Milas,et al.  Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II , 2001, Annals of Internal Medicine.

[585]  H. Parving,et al.  Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. , 2000, Diabetes care.

[586]  G. Lip.  Hypertension and the prothrombotic state , 2000, Journal of Human Hypertension.

[587]  C. Bulpitt,et al.  Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension , 2000, Circulation.

[588]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[589]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[590]  N. Delanty,et al.  Hypertensive emergencies , 2000, The Lancet.

[591]  S. Johnston,et al.  Ischemic stroke risk with oral contraceptives: A meta-analysis. , 2000, JAMA.

[592]  J. Staessen,et al.  Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. , 2000, Archives of internal medicine.

[593]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[594]  D. Levy,et al.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.

[595]  G. Leoncini,et al.  Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. , 1999, Journal of hypertension.

[596]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[597]  T. Hedner.  Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. , 1999, Blood pressure.

[598]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[599]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[600]  J. Cutler,et al.  Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. , 1998, Archives of internal medicine.

[601]  G. Parati,et al.  Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study , 1998, Journal of hypertension.

[602]  P. Whelton,et al.  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.

[603]  David R. Jones,et al.  Automated, ambulatory, or conventional blood pressure measurement in pregnancy: Which is the better predictor of severe hypertension? ☆ ☆☆ ★ ★★ , 1998 .

[604]  G. Parati,et al.  Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the ‘white‐coat’ effect , 1998, Journal of hypertension.

[605]  R. Cooper,et al.  Socioeconomic Status and Health in Blacks and Whites: The Problem of Residual Confounding and the Resiliency of Race , 1997, Epidemiology.

[606]  N. Poulter,et al.  Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994 , 1997, Journal of hypertension.

[607]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[608]  Strategies for antihypertensive treatment decisions: how to assess benefits? , 1997, Journal of hypertension.

[609]  G. Mancia,et al.  White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? , 1996, Journal of hypertension.

[610]  J. Manson,et al.  Prospective study of oral contraceptives and hypertension among women in the United States. , 1996, Circulation.

[611]  L. Fried,et al.  Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. , 1996, Stroke.

[612]  P. Elliott,et al.  Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations , 1996 .

[613]  R. D'Agostino,et al.  Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. , 1996, Circulation.

[614]  G. Schillaci,et al.  White-coat hypertension. , 1996, The Lancet.

[615]  J. Staessen,et al.  Heritability of conventional and ambulatory blood pressures. A study in twins. , 1995, Hypertension.

[616]  Pats-Collaborating-Group-.  Post-stroke antihypertensive treatment study. A preliminary result , 1995 .

[617]  J. Schwartz,et al.  Association of carotid atherosclerosis and left ventricular hypertrophy. , 1995, Journal of the American College of Cardiology.

[618]  Pats,et al.  Post-stroke antihypertensive treatment study. A preliminary result. , 1995, Chinese medical journal.

[619]  J. Staessen,et al.  Efficacy of antihypertensive drugs given once a day: the calcium antagonists revisited , 1994, Journal of Hypertension - Supplement.

[620]  R Doll,et al.  Mortality in relation to smoking: 40 years' observations on male British doctors , 1994, BMJ.

[621]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[622]  P. Palatini,et al.  Factors affecting ambulatory blood pressure reproducibility. Results of the HARVEST Trial. Hypertension and Ambulatory Recording Venetia Study. , 1994, Hypertension.

[623]  R. Collins,et al.  Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. , 1994, British medical bulletin.

[624]  M. Alderman,et al.  Role of Preclinical Cardiovascular Disease in the Evolution From Risk Factor Exposure to Development of Morbid Events , 1993, Circulation.

[625]  G. Parati,et al.  Persistent blood pressure increase induced by heavy smoking. , 1992, Journal of hypertension.

[626]  B. Dahlöf,et al.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.

[627]  K. Radack,et al.  Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. , 1991, Archives of internal medicine.

[628]  T. Pickering,et al.  Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. , 1991, JAMA.

[629]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[630]  W. A. Littler,et al.  USEFULNESS OF OPHTHALMOSCOPY IN MILD TO MODERATE HYPERTENSION , 1989, The Lancet.

[631]  T S Warrender,et al.  Randomised trial of treatment of hypertension in elderly patients in primary care. , 1986, British medical journal.

[632]  L. Kuller,et al.  Systolic Hypertension in the Elderly Program (SHEP) , 1986, Journal of the American Geriatrics Society.

[633]  G. Parati,et al.  Lack of alerting reactions to intermittent cuff inflations during noninvasive blood pressure monitoring. , 1985, Hypertension.

[634]  C. Redman,et al.  FINAL REPORT OF STUDY ON HYPERTENSION DURING PREGNANCY: THE EFFECTS OF SPECIFIC TREATMENT ON THE GROWTH AND DEVELOPMENT OF THE CHILDREN , 1982, The Lancet.

[635]  E. Chester,et al.  Hypertensive encephalopathy , 1978, Neurology.

[636]  C. Redman,et al.  FETAL OUTCOME IN TRIAL OF ANTIHYPERTENSIVE TREATMENT IN PREGNANCY , 1976, The Lancet.

[637]  W. G. Walker,et al.  Plasma aldosterone regulation in anephric man. , 1973, Kidney international.

[638]  T. Kearns,et al.  Prognostic importance of ophthalmoscopic findings in essential hypertension. , 1966, JAMA.

[639]  Tibbs Dj.  MANAGEMENT OF HAEMOPHILIA. , 1965, Lancet.

[640]  J. Groen,et al.  PROGNOSIS OF VASCULAR HYPERTENSION: A Nine Year Follow-Up Study of Four Hundred and Eighteen Cases , 1950 .